Olema Oncology to Present at Upcoming Investor Conferences in November

Rhea-AI Summary

Olema Pharmaceuticals (Nasdaq: OLMA) announces its participation in several investor conferences this November. Key events include a presentation at the Credit Suisse 31st Annual Healthcare Conference on November 9 at 9:10 AM PT, a fireside chat at the Jefferies London Healthcare Conference on November 16 at 11:30 AM GMT, and a virtual fireside chat at the Evercore ISI HealthCONx Conference on November 29 at 2:40 PM ET. Live webcasts and materials will be accessible on Olema's website for at least 30 days.

Olema focuses on developing targeted therapies for women’s cancers, highlighted by its lead product candidate, OP-1250.

SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company will present at the following investor conferences in November:

• Presentation at the Credit Suisse 31^st Annual Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, CA, on Wednesday, November 9, at 9:10 a.m. Pacific Time (12:10 p.m. Eastern Time)
• Fireside chat at the Jefferies London Healthcare Conference at The Waldorf Hilton in London, UK, on Wednesday, November 16, at 11:30 a.m. GMT (6:30 a.m. Eastern Time)
• Virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, at 2:40 p.m. Eastern Time
  

Live webcasts of the presentations and any accompanying presentation materials will be available under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for at least 30 days.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK 4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

IR Contact:
Shane Kovacs, COO and CFO
ir@olema.com

Media Contact:
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
ignacio.guerrero-ros@russopartnersllc.com

FAQ

What presentations will Olema Pharmaceuticals (OLMA) give in November 2022?

Olema Pharmaceuticals will present at the Credit Suisse 31st Annual Healthcare Conference on November 9, a fireside chat at the Jefferies London Healthcare Conference on November 16, and a virtual fireside chat at the Evercore ISI HealthCONx Conference on November 29.

When is Olema's presentation at the Credit Suisse Healthcare Conference?

Olema's presentation at the Credit Suisse 31st Annual Healthcare Conference is scheduled for November 9, 2022, at 9:10 AM Pacific Time.

What is the focus of Olema Pharmaceuticals (OLMA)?

Olema Pharmaceuticals is focused on discovering and developing targeted therapies specifically for women’s cancers.

What is OP-1250 being evaluated for?

OP-1250 is being evaluated as a single agent and in combination with other inhibitors for recurrent, locally advanced or metastatic ER-positive breast cancer.

How can I access Olema's conference presentations?

Live webcasts of Olema's presentations will be available on the company's website and archived for at least 30 days.